Featured News See All November 18, 2024 REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA November 14, 2024 REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202 November 6, 2024 REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates Year All202420232022202120202019201820172016201520142013201220112009 Jan 31, 2024 REGENXBIO Announces Presentations at the 20th Annual WORLDSymposium 2024 Jan 16, 2024 REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery Jan 10, 2024 REGENXBIO Announces Presentation at the Hawaiian Eye and Retina 2024 Meeting Jan 08, 2024 U.S. District Court Issues Decision on REGENXBIO and University of Pennsylvania NAV® Technology Patent Infringement Lawsuit
Jan 16, 2024 REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery
Jan 08, 2024 U.S. District Court Issues Decision on REGENXBIO and University of Pennsylvania NAV® Technology Patent Infringement Lawsuit
